Fundraising Fox

Koutif Therapeutics

Cleveland, US · Founded 2017 · Delaware LLC

Koutif Therapeutics develops therapeutic compounds that inhibit the inflammatory cascade by targeting the ubiquitin degradation pathway, specifically using an inhibitor of the Fbxo3 E3 ligase to degrade pro-inflammatory proteins such as TRAFs and the NLRP3 inflammasome. Its drug discovery approach is based on intellectual property licensed from the University of Pittsburgh and the U.S. Department of Veterans Affairs, aimed at treating inflammatory conditions.

Founders & leadership

Koutif Therapeutics was founded in 2017 by Rama Mallampalli and Beibei Chen.

RM
Rama MallampalliMD
BC
Beibei ChenPhD
BR
Baiju R ShahManager

Reported raises · per SEC filings

Form D private placements

$2.6M disclosed across 1 round · 2017

$2.6MraisedOct 2018 · 3 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Baiju R ShahDirector
Offering amount
$5M
Amount sold
$2.6M
First sale
Sep 2017
Incorporated
Limited Liability Company, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Koutif Therapeutics do?
Koutif Therapeutics develops therapeutic compounds that inhibit the inflammatory cascade by targeting the ubiquitin degradation pathway, specifically using an inhibitor of the Fbxo3 E3 ligase to degrade pro-inflammatory proteins such as TRAFs and the NLRP3 inflammasome. Its drug discovery approach is based on intellectual property licensed from the University of Pittsburgh and the U.S. Department of Veterans Affairs, aimed at treating inflammatory conditions.
Who founded Koutif Therapeutics?
Koutif Therapeutics was founded by Rama Mallampalli, Beibei Chen in 2017.
How much funding has Koutif Therapeutics raised?
Koutif Therapeutics has disclosed $2.6M raised across 1 round.
Where is Koutif Therapeutics headquartered?
Koutif Therapeutics is headquartered in Cleveland, US.